Aktie A1XE3E MAINSTAY MEDICAL INTERNATIONAL
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Mainstay Medical International

Aktien

A1XE3E

IE00BJYS1G50

MSTY

Realtime Euronext Paris
Andere Börsenplätze
 		% 5 Tage % 1. Jan.
- EUR -.--% Intraday Chart für Mainstay Medical International -10,55 % -42,65 %
12.03. Mainstay Medical Holdings plc gibt die Veröffentlichung von klinischen Ergebnissen bekannt, die ältere und jüngere Patienten vergleichen CI
12.02. Mainstay Medical gibt den Erhalt der FDA-Zulassung für die MRT-Kennzeichnung des Reactiv8® Restorative Neurostimulation Systemtm bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Mainstay Medical Holdings plc Announces Publication of Clinical Results Comparing Older Patients and Younger Patients
Mainstay Medical Holdings plc announced that it has received ?115 million in funding from a group of investors
Mainstay Medical Holdings plc announced that it expects to receive funding
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on Reactiv8® Restorative Neurostimulation Systemtm
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States
Mainstay Medical Holdings plc Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-Up Registry of Reactiv8 in the United Kingdom
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2022
Mainstay Medical Holdings plc Announces the Publication of Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact
Esker : Midcap Partners débute le suivi à Achat
Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021
Mainstay Medical Holdings plc Announces Publication of Two-Year Patient Outcomes Data from Reactiv8-B Clinical Trial Demonstrating Long-Term Efficacy of Reactiv8 Restorative Neurostimulation
Mainstay Medical Holdings plc Announces Appointment of Jeffrey Dunn and Eric Major to Its Board of Directors
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2020
Mainstay Medical Announces Limited Announces Commercial Launch of ReActiv8® in US
Oxford Finance LLC Announces Closing of $50 Million Senior Secured Term Loan with Mainstay Medical Holdings plc
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia
Mainstay Medical Holdings plc announced that it has received $108 million in funding from Ally Bridge Group, KCK Group, Sofinnova Partners SAS, Fountain Healthcare Partners, and another investor
Mainstay Medical Holdings plc announced a financing transaction
Mainstay Medical Holdings plc Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1XE3E Aktie
  4. Nachrichten Mainstay Medical International
  5. Andere Sprachen